At the University of Arkansas Myeloma Institute for Research and Therapy, a participatory model of care has improved patient outcomes and may lower the cost of treatment. This patient-partnered model allows patients to participate in treatment decisions, including location of care (in- or outpatient, when applicable), and to self-administer intravenous and subcutaneous medications. In addition, caregivers are significantly involved, and an emphasis is placed on outpatient therapy, patient education, and patient networking. Read More ›
On April 28, 2011, the US Food and Drug Administration (FDA) approved abiraterone acetate (Zytiga, Johnson & Johnson) for the treatment of metastatic castration-resistant prostate cancer (CRPC) for patients who have failed docetaxel therapy. Prostate cancer is a leading cause of cancer mortality and morbidity in the United States.1,2 Each year approximately 215,000 men are diagnosed and 32,000 men die of the disease. Read More ›
Navigators in the Tampa Bay area facilitate the provision of individualized care to help patients receive timely diagnostic resolution of abnormal breast and/or colorectal cancer screenings and get timely treatment. They address a multitude of issues related to transportation, insurance, family support, fear, and other emotions involved with a cancer diagnosis as well as the complexities of the healthcare system, said Ercilia R. Calcano, administrator of the Patient Navigator Research Program (PNRP) at H. Lee Moffitt Cancer Center in Tampa, Florida. Read More ›
As the incidence of invasive fungal infections has risen over the past 20 years, so has the level of concern among oncology nurses. In an interview with The Oncology Nurse-APN/PA, Brenda Shelton, MS, RN, CCRN, AOCN, clinical nurse specialist, The Sidney Kimmel Comp rehensive Cancer Center at Johns Hopkins, Baltimore, Maryland, discusses who is at risk, how nurses can identify them, and steps nurses can take to help these patients. Read More ›
In December of 2009, Lisa M. Schnabel’s husband was diagnosed with glioblastoma, after 20 years of marriage with 3 teenaged children. Schnabel began working as a physician’s assistant in oncology the month she got married in 1989 and has been in her same position since. Her husband had been involved in medicine for as many years. He supported me through long hours and nursing children without a complaint. He even took a research job at the National Institutes of Health in pediatric oncology, so they would have lots to talk about over the dinner table.
Jupiter Medical Center’s Ella Millbank Foshay Cancer Center offers cancer trials in and for its Florida community. But providing care close to home is just part of the oncology clinical research nurse’s role in the clinical trials unit. Read More ›
Lynch syndrome, also called hereditary nonpolyposis colorectal cancer (HNPCC), is the most common cause of hereditary endometrial cancer. It accounts for at least 2% to 3% of all endometrial cancer cases and 9% to 10% of endometrial cancer cases in women diagnosed younger than 50 years of age.1-3 Women with Lynch syndrome have a high lifetime risk for colorectal (30%- 52%)4 and endometrial (20%-71%)5 cancer. Read More ›
SAN FRANCISCO—A novel smallcaliber metal stent can provide a low-risk means of palliation for severe malignant dysphagia, according to investigators who have created these stents and are now testing them in trials. The results were presented at the 2011 Gastrointestinal Cancers Symposium by Stephen Kucera, MD, of H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, where he is an interventional endoscopy fellow. Read More ›
Mayo Clinic investigators and collaborators from the United Kingdom cured well-established prostate tumors in mice using a human vaccine with no apparent side effects. This novel cancer treatment approach encourages the immune system to rid itself of prostate tumors without assistance from toxic chemotherapies and radiation treatments. Such a treatment model could some day help people to live tumor free with fewer side effects than those experienced from current therapies.
To sign up for our newsletter or print publications, please enter your contact information below.
